Article Details
Retrieved on: 2025-03-01 19:02:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a study on zervimesine (CT1812) by Cognition Therapeutics, highlighting its potential to treat dry AMD by targeting pathways related to aging-associated eye diseases, while also focusing on Alzheimer's and dementia treatment.
Article found on: www.modernretina.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here